Teva Pharmaceutical has been showing a notable momentum in the bio-tech market, with its stocks attaining a five-year high. Key reasons behind this surge comprise successful Q1 results and a promising schizophrenia treatment, alongside other victories in various drug trials. The company's CFO and Chief Accounting Officer have recently sold significant shares, yet the company remains a popular choice among institutional investors who hold about 65% of its total stocks. Meanwhile, concerns reach its balance sheet stability and threats from FTC's patent enforcement. Despite this, analysts indicate the company's stock as undervalued and its potential of delivering significant returns. As it continues to make as a separate business and seeks FDA approval for new drugs, its future earnings are anticipated to increase. Nevertheless, Teva inked a $1.5 billion deal for an inflammation drug, prompting a dip in stock value. It is also facing a kickback lawsuit by its investors. Piper Sandler reaffirmed Teva's stock rating amid these developments.
Teva Pharmaceutical Stocks News Analytics from Wed, 02 Aug 2023 07:00:00 GMT to Sat, 18 May 2024 23:04:00 GMT -
Rating 4
- Innovation -3
- Information 6
- Rumor -1
